UPDATE: Aldeyra Therapeutics (ALDX) PT Raised to 'Street High' $35 at Canaccord Genuity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Burry doubles down on Nebius short after stock surges 34% on earnings
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Home Depot CEO Ted Decker takes medical leave; two executives step in
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Aldeyra Therapeutics (ALDX) Prices 5.25M Share Common Offering at $13.75/Sh
September 28, 2018 5:34 AM EDTAldeyra Therapeutics, Inc. (NASDAQ: ALDX) today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $13.75 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering... More
Aldeyra Therapeutics (ALDX) PT Raised to 'Street High' $30 at Cantor Fitzgerald
September 26, 2018 9:33 AM EDTCantor Fitzgerald analyst Elemer Piros raised the price target on Aldeyra Therapeutics (NASDAQ: ALDX) to $30.00 (from $23.00) while maintaining an Overweight rating. The new price target is a 'Street High'.
Prios commented, "We are reiterating our OW rating and raising our 12-month PT to... More
Aldeyra Therapeutics (ALDX) Reports Positive Results from Phase 2b Dry Eye Disease Clinical Trial
September 26, 2018 7:01 AM EDTAldeyra Therapeutics, Inc. (NASDAQ: ALDX) today announced positive results from its Phase 2b clinical trial of topical ocular reproxalap in patients with dry eye disease.
"The early onset and broad activity observed in the Phase 2b clinical trial suggests that reproxalap could be an... More
